The role of IL-1 in gout: from bench to bedside.

Détails

ID Serval
serval:BIB_19CC9E5E368F
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
The role of IL-1 in gout: from bench to bedside.
Périodique
Rheumatology
Auteur(s)
So A., Dumusc A., Nasi S.
ISSN
1462-0332 (Electronic)
ISSN-L
1462-0324
Statut éditorial
Publié
Date de publication
01/01/2018
Peer-reviewed
Oui
Volume
57
Numéro
suppl_1
Pages
i12-i19
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't ; Review
Publication Status: ppublish
Résumé
The translation of our knowledge of the biology of MSU crystal-induced IL-1 secretion gives rise to new targets and therapeutic strategies in the treatment of acute gout. The NACHT, LRR and PYD domains-containing protein 3 inflammasome is key to this, and is the subject of intense research. Novel pathways that modulate inflammasome activation, reactive oxygen species generation and extracellular processing of IL-1 have been described and show promise in in vitro and animal studies. Meanwhile, blocking IL-1 by various IL-1 inhibitors has shown the validity of this concept. Patients with acute gout treated with these inhibitors showed positive clinical and biological responses. More work needs to be performed to assess the risk/benefit profile of anti-IL-1 therapies as well as to identify those who will benefit the most from this novel approach to the treatment of gout.
Mots-clé
Animals, Gout/metabolism, Humans, Inflammasomes/metabolism, Interleukin-1beta/metabolism, Macrophages/metabolism, IL-1, anti-cytokine therapy, gout, inflammasome, inflammation
Pubmed
Web of science
Open Access
Oui
Création de la notice
13/01/2018 11:59
Dernière modification de la notice
20/08/2019 12:50
Données d'usage